SurroMed presses on with cancer diagnostics:
This article was originally published in Clinica
Biomarker company SurroMed has teamed up with the Comprehensive Cancer Center of Wake Forest University to develop novel diagnostics in prostate and renal cell cancer. The collaboration will involve a portion of the cancer targets that the Mountain View, California firm acquired in a transaction announced earlier this year with the company PPD, a provider of discovery and development services and products for pharmaceutical and biotechnology companies. "This is the first step in our programme to develop novel cancer diagnostics based on differential protein and metabolite profiling," said Gordon Ringold, SurroMed's CEO and chairman.